GlobeNewswire Inc.··NaLyell Immunopharma Secures $50M Funding Tranche on Clinical Progress
Lyell Immunopharma closes $50M funding tranche, advances ronde-cel in pivotal lymphoma trial, appoints new CFO with extended cash runway through Q2 2027.
LYELCAR T-cell therapycash runway